New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
10:07 EDTPKOH, BRO, SKS, EBAY, STRZA, MMC, CHMT, SRPT, RHT, FOR, WPRT, OMCL, BMR, ACT, BXP, AON, ACN, BIOS, AMZNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accenture (ACN) initiated with an Overweight at Evercore... Actavis (ACT) initiated with an Overweight at Morgan Stanley... Amazon.com (AMZN) initiated with a Buy at ISI Group... Aon Corp. (AON) initiated with a Market Perform at Wells Fargo... BioMed Realty (BMR) initiated with a Neutral at Goldman... BioScrip (BIOS) initiated with a Buy at SunTrust... Boston Properties (BXP) initiated with an Overweight at Evercore... Brown & Brown (BRO) initiated with a Market Perform at Wells Fargo... Forestar Group (FOR) initiated with a Buy at DA Davidson... Marsh & McLennan (MMC) initiated with an Outperform at Wells Fargo... Park-Ohio (PKOH) initiated with an Outperform at Imperial Capital... Red Hat (RHT) initiated with an Outperform at Northland Securities... Starz (STRZA) initiated with a Sell at Stifel Nicolaus... Starz (STRZA) initiated with an Underweight at Evercore... Omnicell (OMCL) initiated with a Buy at Benchmark Co... Sarepta (SRPT) initiated with an Outperform at Cowen... eBay (EBAY) initiated with a Positive at Susquehanna... Westport Innovations (WPRT) initiated with a Market Perform at Raymond James... Chemtura (CHMT) initiated with a Buy at Sidoti... Saks (SKS) initiated with a Buy at Maxim.
News For ACN;ACT;AMZN;AON;BMR;BIOS;BXP;BRO;FOR;MMC;PKOH;RHT;STRZA;OMCL;SRPT;EBAY;WPRT;CHMT;SKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 13, 2015
13:42 EDTACTActavis targeting 2017 EPS of $25
Subscribe for More Information
13:38 EDTACTActavis sees Q4 adjusted EPS beating consensus by 10%-15%
Subscribe for More Information
10:30 EDTAMZNAmazon.com tests $300, levels to watch
Subscribe for More Information
10:00 EDTAMZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:01 EDTAMZNAmazon Studios signs Woody Allen to create television series
Subscribe for More Information
08:05 EDTACTActavis launches US generic specialty injectable portfolio
Actavis announced the launch of a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The company hopes to be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration, as well as more than 50 additional projects currently in development.
07:30 EDTWPRTDeutsche Bank to hold a conference
Subscribe for More Information
07:28 EDTAMZNAmazon says created, filled over 6,000 permanent jobs across EU in 2014
Subscribe for More Information
07:26 EDTAMZNAmazon.com survey suggests solid growth trends, says RW Baird
Baird said their recent inventory survey for Amazon.com suggests solid growth trends in selection and marketplace. The firm sees the selection as a key growth driver for Amazon retail. Baird reiterated its Outperform rating and $340 price target on Amazon shares.
06:18 EDTEBAYSilicon Valley shuttle drivers looking to unionize, USA Today reports
Subscribe for More Information
06:16 EDTAMZNAmazon.com upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Amazon.com to Buy saying the risk/reward on shares is attractive below $300. Citi believes holiday data points look good for Amazon's Q4 results and that the retailer's gross margins will rise in 2015, reversing 2014's downward trend. The firm raised its price target for Amazon to $354 from $325 and thinks the stock has support around $300. Shares of the retailing giant closed yesterday down $5.52 to $291.41.
06:07 EDTAMZNAmazon sued for $25M by Durst Organization, Forbes reports
Subscribe for More Information
January 12, 2015
17:21 EDTOMCLOak Ridge Investments reports 6.56% passive stake in Omnicell
16:32 EDTSRPTOn The Fly: Closing Wrap
Stocks spent almost the entire session in negative territory as the continued slump in crude oil prices weighed on equities. As the price of crude searches for a bottom, analysts and investors are concerned about how the low prices may affect U.S. economic growth. It had been estimated that more than half of the expected growth in the S&P 500's earnings would come from the oil industry and the continued drop in oil prices may be wiping out the chances of earnings increasing from the prior quarter. The earnings season unofficially kicks off tonight when Alcoa (AA) reports its fourth quarter earnings. ECONOMIC EVENTS: In the U.S., no major economic data was released. WTI and Brent crude both suffered slides of 5% during the session, sending WTI oil below $46 and Brent near $47 per barrel. Of note, Goldman Sachs said it sees oil prices bottoming in Q2 of this year at $42 a barrel. Goldman lowered its Brent crude oil price estimate for 2015 to $50 a barrel from $84 and for 2016 onwards to $70 a barrel from $90. COMPANY NEWS: Shire (SHPG) shares trading in New York slipped $8.39, or 3.86%, to $209.10 after the company announced over this weekend that it struck a deal to acquire NPS Pharmaceuticals (NPSP) for $46 per share in cash, for a total consideration of approximately $5.2B. NPS shares gained $3.44, or 8.21%, to $45.35... Shares of flash storage provider SanDisk (SNDK) dropped $13.47, or 13.88%, to $83.57 after the company cut its revenue outlook for Q4 and added that non-GAAP gross margin for the quarter is expected to be approximately 45%, compared to the previously guided range of 47%-49%. "The lower revenue was primarily due to weaker than expected sales of retail and iNAND products," SanDisk explained. Micron (MU) fell $1.87, or 5.56%, to $31.66 following the warning from its peer. MAJOR MOVERS: Among the notable gainers was Foundation Medicine (FMI), whose shares surged $22.81, or 95.32%, to $46.74 after the company and Roche (RHHBY) announced that they will enter into a strategic collaboration. Roche will invest in Foundation as part of the deal, resulting in Roche owning a minimum of 52.4% and a maximum of 56.3% of Foundation Medicine on a fully diluted basis. Also higher was Build-A-Bear Workshop (BBW), which jumped $3.12, or 16.75%, to $21.75 after the toy company gave a fourth quarter revenue view that beat expectations. Among the noteworthy losers was Arrowhead Research (ARWR), which fell $2.16, or 23.84%, to $6.90 after announcing that the FDA verbally informed the company of a partial clinical hold on its study of ARC-520 in patients with chronic hepatitis B infection. Also lower were shares of Sarepta Therapeutics (SRPT), which dropped $2.04, or 14.62%, to $11.91 after the company provided data through Week 168 from its Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy. INDEXES: The Dow fell 96.53, or 0.54%, to 17,640.84, the Nasdaq lost 39.36, or 0.84%, to 4,664.71, and the S&P 500 declined 16.55, or 0.81%, to 2,028.26.
16:00 EDTAMZNOptions Update; January 12, 2015
iPath S&P 500 VIX Short-Term Futures up 1.57 to 33.54. Option volume leaders: AAPL TSLA TWTR AMZN AA SIRI RIG FRO C according to Track Data.
13:31 EDTEBAYPayPal providing new credit options
eBay's PayPal earlier today announced that, for the first time, by leveraging new credit models retailers can customize PayPal Credit will offer a monthly payment option and decide on the number of months and interest rate that works best for their customers. They can also offer interest free options to customers shopping online who are approved in minutes, the payment service said. The new PayPal Credit feature works within the open-ended construct of the PayPal Credit product, allowing customers to divide their larger purchases into substantially equal monthly payments, PayPal stated. This gives consumers more control and helps them to better manage their budget, it added.
12:45 EDTACTActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
12:10 EDTACTRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
11:14 EDTSRPTDenver patient being tested for Ebola, KUSA-TV reports
A patient recently returned from Ebola affected areas in Africa is being tested in Denver for the disease, reported local NBC affiliate 9New KUSA-TV. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE) and Alpha Pro Tech (APT). Reference Link
09:37 EDTACTSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use